BTIG Research upgraded shares of Embecta (NASDAQ:EMBC – Free Report) from a neutral rating to a buy rating in a research report sent to investors on Wednesday, Marketbeat reports. BTIG Research currently has $26.00 price target on the stock.
Embecta Trading Up 10.1 %
Embecta stock opened at $20.59 on Wednesday. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of 17.16 and a beta of 0.97. The firm’s fifty day moving average price is $14.38 and its two-hundred day moving average price is $14.07. Embecta has a 1-year low of $9.93 and a 1-year high of $20.80.
Embecta Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Friday, December 6th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 2.91%. The ex-dividend date of this dividend is Friday, December 6th. Embecta’s dividend payout ratio (DPR) is presently 50.00%.
Institutional Inflows and Outflows
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
See Also
- Five stocks we like better than Embecta
- How to Calculate Inflation Rate
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is the NASDAQ Stock Exchange?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Dividend Capture Strategy: What You Need to Know
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.